Argenx Shares Plunge on Regulatory Uncertainty as Trading Volume Tumbles 31.24 to Rank 481st

On September 12, 2025, , , . .

Recent developments highlight regulatory scrutiny intensifying for argenx as the FDA’s advisory panel schedules an October 15 review of its investigational drug efgartigimod for generalized myasthenia gravis. The panel’s recommendation could delay or accelerate the drug’s approval timeline, creating near-term uncertainty for investors.

Analysts noted mixed signals from clinical trial data disclosed in late August. While showed efgartigimod maintained efficacy in reducing antibody levels over 24 weeks, secondary endpoints revealed inconsistent symptom improvement in subgroups. This duality has led to cautious positioning among , with reduced short-term liquidity observed in the options market.

To run this back-test rigorously I need to pin down a couple of details: 1. Market universe • Do you want the “top-500 by daily volume” selected from all U.S. listed common stocks, or from another universe (e.g., S&P 500 constituents, a specific exchange, or a different country)? 2. Re-balancing mechanics • Should the portfolio be formed at the close of day t (buy 500 stocks), then liquidated at the close of day t + 1? • Equal-weight each position, or weight by (for example) dollar volume or market-cap? 3. Transaction costs / slippage • Should we assume zero costs, or do you want to embed a commission or ? Once I have those three items I can generate the data-retrieval plan and run the back-test from 2022-01-01 through today.